Spotlight
Video

Trial updates in NHL: RELEVANCE, polatuzumab, TRANSCEND-NHL-001 & Hu5F9-G4

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: Cutting-edge trial data in the field of lymphoma was presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. Here, Nathan Fowler, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the key data on show. Prof. Fowler, who presented data from the RELEVANCE trial (NCT01476787), highlights the promising results from the combination of bendamustine-rituximab plus the antibody-drug conjugate polatuzumab vedotin (NCT02257567) for relapsed/refractory follicular and diffuse large B-cell lymphoma. In addition, he picks out the TRANSCEND-NHL-001 trial (NCT02631044) of CAR T-cell product lisocabtagene maraleucel, and a trial of a promising novel anti-CD47 antibody, Hu5F9-G4 (NCT02953509), both for relapsed/refractory non-Hodgkin lymphoma.
Shared By : VJHemOnc
Posted on : 07/30/18
Added : 12 months ago
Category : Lymphoma